|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||10.31 - 10.50|
|52 Week Range||9.84 - 17.48|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Arya Sciences Acquisition Corp. (NASDAQ: ARYA or "Arya"), a special purpose acquisition company sponsored by Perceptive Advisors, and Immatics Biotechnologies GmbH ("Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced that its respective shareholders approved the business combination between Arya and Immatics announced on March 17, 2020. None of Arya’s shareholders redeemed their shares in connection with the ARYA shareholder approval. The respective boards of directors of both Arya and Immatics had previously approved the business combination.
NEW YORK, NY / ACCESSWIRE / June 17, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Arya Sciences Acquisition Corp. ("Arya Sciences" or the "Company") (NasdaqGS: ARYA) relating its combination with Immatics B.V., a Netherlands private limited company. Under the terms of the agreement, each outstanding share of Arya common stock, will be automatically exchanged for one share of the newly formed company, Immatics N.V.